Geoff Oxnard

Geoff Oxnard, M.D., joined BlossomHill Therapeutics as executive vice president and chief medical officer after a 15-year career in cancer research spanning industry and academia. Dr. Oxnard is a globally recognized clinical and translational cancer investigator who spent nearly 10 years on faculty at the Dana-Farber Cancer Institute and Harvard Medical School. His research work focused on molecular drivers of sensitivity and resistance to precision cancer therapies and the application of molecular diagnostics to advance cancer care and drug development. He has authored nearly 200 scientific publications, including leading the first description of the EGFR C797S resistance mutation, reported in Nature Medicine in 2015. Prior to joining BlossomHill, Dr. Oxnard served as vice president, global head of thoracic cancers at Eli Lilly (formerly Loxo Oncology), where he accelerated the early and late-phase development of a diverse thoracic portfolio. He previously served as senior vice president, head of clinical development at Foundation Medicine, where he supported the FDA approval of FoundationOne®Liquid CDx and the launch of an emerging ctDNA monitoring portfolio. Dr. Oxnard continues to see patients part-time as a thoracic oncologist at Boston Medical Center, a safety-net hospital in Boston.

Dr. Oxnard received his medical degree from the University of Chicago-Pritzker School of Medicine. He completed his residency in internal medicine at Massachusetts General Hospital and completed a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center in New York City. He has been a recipient of numerous awards, including a Career Development Award from the Conquer Cancer Foundation of ASCO (2010), a Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (2016), a Clinical Investigator Award from the Damon Runyon Cancer Research Foundation (2016), and recognition as a Fellow of the American Society of Clinical Oncology (2023).